← FDA DRUG APPROVALS

FDA ANDA · ANDA040266

METHOTREXATE

methotrexate sodium

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA040266
TYPE
ANDA
ORIGINAL APPROVAL
1999-02-26
LATEST ACTION
2024-08-27
ROUTE
INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

METHOTREXATE PRESERVATIVE FREEPrescription
METHOTREXATE SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-08-27Labeling · Supplement 22 · standardAP
2023-09-18Labeling · Supplement 17 · standardAP
2021-09-14Labeling · Supplement 16 · standardAP
2021-09-14Labeling · Supplement 12 · standardAP
2017-03-03Labeling · Supplement 11 · standardAP
2012-09-28Labeling · Supplement 7AP
2000-01-24Manufacturing (CMC) · Supplement 1AP
1999-02-26OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →